India Leads the Way in Affordable Ozempic: A Global Shift in Access to Weight-Loss Drugs
India has become the first major market to see the launch of generic versions of Novo Nordisk’s blockbuster drugs Ozempic and Wegovy, significantly undercutting the prices of the brand-name medications. This development has implications for global access to these drugs, particularly for individuals with diabetes and obesity, but Canada remains on the sidelines awaiting regulatory approval for its own generic versions.
Price Disparity: India vs. Canada
Indian pharmaceutical companies, including Sun Pharmaceutical and Dr. Reddy’s Laboratories, have launched generic semaglutide – the active ingredient in both Ozempic and Wegovy – at prices up to 80% lower than Novo Nordisk’s retail prices in India. Sun Pharma’s Noveltreat and Sematrinity are priced between 900 and 2,000 rupees (approximately $11 to $24 USD), while Dr. Reddy’s Obeda is available for around 4,200 rupees ($62 USD). Natco Pharma Ltd. Plans to offer a monthly supply for approximately 1,290 rupees ($14 USD).1
In contrast, Ozempic currently lists for $223 in Canada for a four-week supply, with patients often paying more after pharmacy and distributor markups.4 While Canada approved generic Ozempic for legal sale on January 5th, no generic versions have yet been approved for market.4
A Surge in Generic Manufacturers
Over 40 Indian drugmakers are poised to enter the generic semaglutide market, creating a competitive landscape. Companies like Cipla, Biocon, Mankind, Lupin, and Zydus have all announced plans to launch their versions of the drug.2 Lupin and Zydus have even established licensing and supply collaborations to maximize their market reach.2
India’s Role as the “World’s Pharmacy”
India’s position as a major producer of generic drugs – supplying around 20% of the global off-patent medicine market – is a key factor in this price reduction.1 With a large population – approximately 100 million people living with diabetes and nearly a quarter classified as obese – India represents a significant market for GLP-1 drugs.1
Implications for Canada and Global Access
Despite Canada being the first major market to legalize generic Ozempic, Indian manufacturers are beating their Canadian counterparts to market. Dr. Reddy’s and Sun Pharma have both submitted applications to Health Canada, but approvals are still pending.4
The launch of cheaper generic versions in India is expected to democratize access to GLP-1 drugs worldwide, with Dr. Reddy’s planning to expand sales of its generic semaglutide to Canada, Turkey, and Brazil.1 Yet, experts caution that increased availability could lead to misuse, self-medication, and potential side effects if not properly managed.2
Market Impact and Future Outlook
Novo Nordisk has responded to the increased competition by cutting prices and forming partnerships to defend its market share in India.1 The coming weeks are anticipated to be “chaotic” as companies engage in aggressive marketing campaigns.2 Ozempic and Wegovy remain significant drugs in Canada, earning a combined $3.5 billion in 2025.4